Influenza virus hemagglutinin fusion protein production — foot-and-mouth-disease virus, poliovirus, human rhinovirus, hepatitis B virus or Plasmodium falciparum recombinant vaccine production in vaccinia virus vector

Vaccine ◽  
1994 ◽  
Vol 12 (2) ◽  
pp. 190
2000 ◽  
Vol 68 (1) ◽  
pp. 35-49 ◽  
Author(s):  
Andreas Berting a, ◽  
Christian Fischer ◽  
Stephan Schaefer ◽  
Wolfgang Garten ◽  
Hans-Dieter Klenk ◽  
...  

2017 ◽  
Vol 91 (22) ◽  
Author(s):  
Michael Puckette ◽  
Benjamin A. Clark ◽  
Justin D. Smith ◽  
Traci Turecek ◽  
Erica Martel ◽  
...  

ABSTRACT The foot-and-mouth disease virus (FMDV) afflicts livestock in more than 80 countries, limiting food production and global trade. Production of foot-and-mouth disease (FMD) vaccines requires cytosolic expression of the FMDV 3C protease to cleave the P1 polyprotein into mature capsid proteins, but the FMDV 3C protease is toxic to host cells. To identify less-toxic isoforms of the FMDV 3C protease, we screened 3C mutants for increased transgene output in comparison to wild-type 3C using a Gaussia luciferase reporter system. The novel point mutation 3C(L127P) increased yields of recombinant FMDV subunit proteins in mammalian and bacterial cells expressing P1-3C transgenes and retained the ability to process P1 polyproteins from multiple FMDV serotypes. The 3C(L127P) mutant produced crystalline arrays of FMDV-like particles in mammalian and bacterial cells, potentially providing a practical method of rapid, inexpensive FMD vaccine production in bacteria. IMPORTANCE The mutant FMDV 3C protease L127P significantly increased yields of recombinant FMDV subunit antigens and produced virus-like particles in mammalian and bacterial cells. The L127P mutation represents a novel advancement for economical FMD vaccine production.


Vaccine ◽  
2019 ◽  
Vol 37 (12) ◽  
pp. 1674-1684 ◽  
Author(s):  
Natalie J. Kingston ◽  
Liriye Kurtovic ◽  
Renae Walsh ◽  
Carina Joe ◽  
George Lovrecz ◽  
...  

2004 ◽  
Vol 72 (11) ◽  
pp. 6519-6527 ◽  
Author(s):  
Elizabeth H. Nardin ◽  
Giane A. Oliveira ◽  
J. Mauricio Calvo-Calle ◽  
Kristiane Wetzel ◽  
Carolin Maier ◽  
...  

ABSTRACT We report the first phase I trial to assess the safety and immunogenicity of a malaria vaccine candidate, ICC-1132 (Malarivax), composed of a modified hepatitis B virus core protein (HBc) containing minimal epitopes of the Plasmodium falciparum circumsporozoite (CS) protein. When expressed in Escherichia coli, the recombinant ICC-1132 protein forms virus-like particles that were found to be highly immunogenic in preclinical studies of mice and monkeys. Twenty healthy adult volunteers received a 20- or a 50-μg dose of alum-adsorbed ICC-1132 administered intramuscularly at 0, 2, and 6 months. The majority of volunteers in the group receiving the 50-μg dose developed antibodies to CS repeats as well as to HBc. Malaria-specific T cells that secreted gamma interferon were also detected after a single immunization with ICC-1132-alum. These studies support ICC-1132 as a promising malaria vaccine candidate for further clinical testing using more-potent adjuvant formulations and confirm the potential of modified HBc virus-like particles as a delivery platform for vaccines against other human pathogens.


Sign in / Sign up

Export Citation Format

Share Document